GSK
930 hedge funds and large institutions have $14.4B invested in GSK in 2022 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 350 increasing their positions, 275 reducing their positions, and 79 closing their positions.
66% more call options, than puts
Call options by funds: $342M | Put options by funds: $206M
32% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 79
27% more repeat investments, than reductions
Existing positions increased: 350 | Existing positions reduced: 275
1% more funds holding
Funds holding: 919 → 930 (+11)
0% less ownership
Funds ownership: 5.21% → 5.21% (-0%)
0% less capital invested
Capital invested by funds: $14.5B → $14.4B (-$18.3M)
11% less funds holding in top 10
Funds holding in top 10: 19 → 17 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
+$131M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$103M |
| 3 |
Goldman Sachs
New York
|
+$101M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$96.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$70M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$120M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$106M |
| 3 |
Two Sigma Investments
New York
|
-$83.2M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$65.2M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$57.3M |
GSK Hedge Fund Activity: Q1 2022 in Review
930 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2022, worth a combined $14.4B — down 0.13% from $14.5B a quarter earlier.
Buyers outnumbered sellers: 104 funds opened new GSK positions and 79 closed out — a net gain of 25 holders — while 350 added to existing stakes and 275 trimmed.
The largest buyer was JTC Employer Solutions Trustee, adding an estimated $131M. The largest seller was Dodge & Cox, cutting an estimated $120M.
- 930 institutional investors held GSK (GSK) as of Q1 2022, up from 919 in Q4 2021.
- Funds reported $14.4B of GSK stock for Q1 2022, down 0.13% quarter-over-quarter.
- 104 funds opened new GSK positions in Q1 2022 and 79 closed out, a net change of +25 holders.
- The largest GSK buyer in Q1 2022 was JTC Employer Solutions Trustee, an estimated $131M added.
- The largest GSK seller in Q1 2022 was Dodge & Cox, an estimated $120M sold.
Based on aggregated 13F filings for Q1 2022.